Orchestra BioMed to Participate in the Piper Sandler 36th Annual Healthcare Conference
26 Novembro 2024 - 6:05PM
Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed”
or the “Company”), a biomedical company accelerating high-impact
technologies to patients through risk-reward sharing partnerships,
today announced that company management will present and be
available for one-on-one meetings at the Piper Sandler 36th Annual
Healthcare Conference being held in New York, NY from December 3-5,
2024.
Details of the presentation are shown below.
Format: Fireside ChatDate: Wednesday, December 4, 2024Time: 3:00
PM
ESTWebcast: https://event.webcasts.com/starthere.jsp?ei=1700018&tp_key=660c0503d6
A replay of the webcast will be available on the Events section
of the Orchestra BioMed website for 90 days following the
presentation.
About Orchestra BioMedOrchestra BioMed (Nasdaq:
OBIO) is a biomedical innovation company accelerating high-impact
technologies to patients through risk-reward sharing partnerships
with leading medical device companies. Orchestra BioMed’s
partnership-enabled business model focuses on forging strategic
collaborations with leading medical device companies to drive
successful global commercialization of products it develops.
Orchestra BioMed’s lead product candidate is atrioventricular
interval modulation (AVIM) therapy (also known as BackBeat Cardiac
Neuromodulation Therapy (CNT™)) for the treatment of hypertension,
a significant risk factor for death worldwide. Orchestra BioMed is
also developing Virtue® Sirolimus AngioInfusion™ Balloon (SAB) for
the treatment of atherosclerotic artery disease, the leading cause
of mortality worldwide. Orchestra BioMed has a strategic
collaboration with Medtronic, one of the largest medical device
companies in the world, for development and commercialization of
AVIM therapy for the treatment of hypertension in
pacemaker-indicated patients, and a strategic partnership with
Terumo, a global leader in medical technology, for development and
commercialization of Virtue SAB for the treatment of artery
disease. For further information about Orchestra BioMed, please
visit www.orchestrabiomed.com, and follow us on LinkedIn.
References to Websites and Social Media
Platforms
References to information included on, or accessible through,
websites and social media platforms do not constitute incorporation
by reference of the information contained at or available through
such websites or social media platforms, and you should not
consider such information to be part of this press release.
Contact:Kelsey Kirk-EllisOrchestra
BioMed484-682-4892Kkirkellis@orchestrabiomed.com
Orchestra BioMed (NASDAQ:OBIO)
Gráfico Histórico do Ativo
De Nov 2024 até Dez 2024
Orchestra BioMed (NASDAQ:OBIO)
Gráfico Histórico do Ativo
De Dez 2023 até Dez 2024